BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30840263)

  • 41. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
    Chen H; Tian X; Luan Y; Lu H
    Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Downregulation of miR-22 acts as an unfavorable prognostic biomarker in osteosarcoma.
    Wang G; Shen N; Cheng L; Lin J; Li K
    Tumour Biol; 2015 Sep; 36(10):7891-5. PubMed ID: 25953260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CCEPR is a novel clinical biomarker for prognosis and regulates cell proliferation through PCNA in osteosarcoma.
    Teng J; Guo X; Wang H
    J Cell Biochem; 2019 Aug; 120(8):12796-12802. PubMed ID: 30861164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma.
    Guo Z; Tang Y; Fu Y; Wang J
    Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Up-regulation of miR-130b expression level and down-regulation of miR-218 serve as potential biomarker in the early detection of human osteosarcoma.
    Taheriazam A; Talaei AJ; Jamshidi M; Shakeri M; Khoshbakht S; Yahaghi E; Shokrani M
    Diagn Pathol; 2015 Oct; 10():184. PubMed ID: 26446495
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LncRNA CCAT2 enhances cell proliferation via GSK3β/β-catenin signaling pathway in human osteosarcoma.
    Ruan R; Zhao XL
    Eur Rev Med Pharmacol Sci; 2018 May; 22(10):2978-2984. PubMed ID: 29863240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
    Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
    Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo.
    Qiao S; Qi K; Liu C; Xu C; Ma J; Xu X; Li C; Wang Z
    J Clin Lab Anal; 2020 May; 34(5):e23164. PubMed ID: 31893577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.
    Zhang P; Xu K; Wang J; Zhang J; Quan H
    BMC Cancer; 2021 Dec; 21(1):1285. PubMed ID: 34852770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma.
    Sun K; Gong C; Peng H; Fang H; Zhou J; Li J; Chen S; Zheng H
    Mol Med Rep; 2017 Nov; 16(5):6953-6957. PubMed ID: 28901496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prognostic value and mechanism of long non-coding RNA DLEU1 in osteosarcoma].
    Zhang JJ; Yang P; Shang XQ
    Zhongguo Gu Shang; 2023 Jun; 36(6):559-64. PubMed ID: 37366099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long non-coding RNA ROR is a novel prognosis factor associated with non-small-cell lung cancer progression.
    Qu CH; Sun QY; Zhang FM; Jia YM
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4087-4091. PubMed ID: 29028092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma.
    Gao KT; Lian D
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3561-5. PubMed ID: 27649655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-1908 is a biomarker for poor prognosis in human osteosarcoma.
    Lian D; Wang ZZ; Liu NS
    Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1258-62. PubMed ID: 27097944
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications.
    Wang L; Aireti A; Aihaiti A; Li K
    Pathol Oncol Res; 2019 Apr; 25(2):527-533. PubMed ID: 30220021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High expression levels of Cyr61 and VEGF are associated with poor prognosis in osteosarcoma.
    Liu Y; Zhang F; Zhang Z; Wang D; Cui B; Zeng F; Huang L; Zhang Q; Sun Q
    Pathol Res Pract; 2017 Aug; 213(8):895-899. PubMed ID: 28647210
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Altered long non-coding RNAs predict worse outcome in osteosarcoma patients: evidence from a meta-analysis.
    Yang Y; Wang S; Li T
    Oncotarget; 2017 May; 8(21):35234-35243. PubMed ID: 28415638
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
    Wang Z; Tan M; Chen G; Li Z; Lu X
    IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased Expression of microRNA-199b-5p Associates with Poor Prognosis Through Promoting Cell Proliferation, Invasion and Migration Abilities of Human Osteosarcoma.
    Zeng H; Zhang Z; Dai X; Chen Y; Ye J; Jin Z
    Pathol Oncol Res; 2016 Apr; 22(2):253-60. PubMed ID: 26183062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.